Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib for Myeloprotection in Chemoradiotherapy for Locally Advanced NPC, Esophageal, and Cervical Cancer
ChiCTR2500110354Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trilaciclib in myelosuppression (3 cohorts), sponsored by Xijing Hospital. Primary endpoint: Proportion of patients without grade III or higher neutropenia. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
myelosuppression
Beyond the preview
Go deeper on ChiCTR2500110354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110354.